Our mission is to revolutionise the field of diagnostics by providing rapid, accurate, and quantified point-of-care testing solutions. We strive to empower healthcare professionals with advanced technologies that enhance speed-to-care, leading to improved patient outcomes and ultimately saving lives. What We Have Delivered - A significant pipeline of tests currently focused on the most important global health challenges: Post-viral syndromes like Long Covid, COVID-19, Liver Health, Diabetes, Obesity, and Antimicrobial Resistance (AMR). Currently the Company’s Long Covid research test is available in the UK, Switzerland, Cyprus with plans to roll out in the USA, India, Singapore and the Cayman Islands. It’s an exciting time for Attomarker but perhaps even more so for the patients served by its innovative gold-based nanophotonic technology. Background - Attomarker is a British company which developed a technology for measuring multiple biomarkers in blood and saliva to provide a multi-dimensional health profile in 7-10 minutes. The data can be used by patients to make more informed decisions about their health, wellbeing and protection, and by healthcare professionals to determine a personalised patient healthcare pathway across multiple healthcare settings at the bedside, in the operating theatre, in the pharmacy and at home. It was founded in 2008, and spun out from Professor Andrew Shaw’s research group at the University of Exeter. It has won numerous prestigious awards for innovation and been awarded grants for research from the UK Government due to the importance of its work. If you wish to find out more about our technology please visit our website www.attomarker.com or contact us directly via email at info@attomarker.com